CI

At a glance

ClinicalIndex Comparison Record
Phase 4Active· 30 target
Drug / intervention
Ocrelizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04466150
NCT04466150Phase 4ActiveOn TrackUpdated 5mo ago
CompareCT.gov

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

University of California, San Francisco·interventional·Posted Jul 10, 2020·Updated Jan 26, 2026

In Brief

A Phase 4 clinical trial evaluating Ocrelizumab for Relapsing Multiple Sclerosis and Clinically Isolated Syndrome. Active but no longer recruiting, targeting 30 participants across 1 site.

Detailed Summary

Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters CSF markers of chronic inflammation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Multiple Sclerosis, Clinically Isolated Syndrome
CountriesUnited States
CollaboratorsGenentech, Inc., Valhalla Foundation

Timeline

Phase 4Active
2021202220232024202520262027
First PostedJul 10, 2020
Enrollment StartAug 30, 2020
Primary CompletionDec 1, 2026
Study CompletionJul 1, 2027
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 6.0 years agoPrimary completion in 5 months

Interventions

Ocrelizumabdrug

open label biomarker study